Pfizer Inc.
METHODS OF TREATING CANCER USING COMBINATION THERAPY

Last updated:

Abstract:

The present application is directed to therapeutic regimens and methods of treating cancer, with the regimens and methods comprising administering to the subject a programmed death-ligand 1 (PD-L1) inhibitor and a recombinant vesicular stomatitis virus that has been engineered to expresses interferon beta (VSV-IFN.beta.-NIS).

Status:
Application
Type:

Utility

Filling date:

21 Jun 2019

Issue date:

19 Aug 2021